Citations

Clear

750 citation(s) found for "Lowe, Val".

First PET Imaging Studies With 63 Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease
DeGrado, Timothy R. , Kemp, Bradley J. , Pandey, Mukesh K. , Jiang, Huailei , Gunderson, Tina M. , Linscheid, Logan, Woodwick, Allison R., McConnell, Daniel, Johnson, Geoffrey B. , Petersen, Ronald C. , Lowe, Val J. , Linscheid, Logan R, McConnell, Daniel M, Fletcher, Joel G. , Knopman, David S. , Johnson, Geoffrey B , Pandey, Mukesh K , Jiang, Huailei

Mayo Clinic

Molecular Imaging | December 10, 2016 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/1536012116673793 | PMID 27941122 Get It

Abnormalities in zinc homeostasis are indicated in many human diseases, including Alzheimer disease (AD). 63 Zn-zinc citrate was developed as a positron emission tomography (PET) imaging probe of zinc transport and used in a first-in-human study in 6 healthy elderly individuals and 6 patients with clinically confirmed AD. Dynamic PET imaging of the brain was performed for 30 minutes following intravenous administration of 63 Zn-zinc citrate (∼330 MBq). Subsequently, body PET images were acquired. Urine and venous blood were analyzed to give information on urinary excretion and pharmacokinetics. Regional cerebral 63 Zn clearances were compared with 11 C-Pittsburgh Compound B ( 11 C-PiB) and 18 F-fluorodeoxyglucose ( 18 F-FDG) imaging data. 63 Zn-zinc citrate was well tolerated in human participants with no adverse events monitored. Tissues of highest uptake were liver, pancreas, and kidney, with moderate uptake being seen in intestines, prostate (in males), thyroid, spleen, stomach, pituitary, and salivary glands. Moderate brain uptake was observed, and regional dependencies were observed in 63 Zn clearance kinetics in relationship with regions of high amyloid-β plaque burden ( 11 C-PiB) and 18 F-FDG hypometabolism. In conclusion, zinc transport was successfully imaged in human participants using the PET probe 63 Zn-zinc citrate. Primary sites of uptake in the digestive system accent the role of zinc in gastrointestinal function. Preliminary information on zinc kinetics in patients with AD evidenced regional differences in clearance rates in correspondence with regional amyloid-β pathology, warranting further imaging studies of zinc homeostasis in patients with AD.
AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
Kantarci, Kejal , Lowe, Val J. , Senjem, Matthew L. , Tosakulwong, Nikki, Lesnick, Timothy G. , Spychalla, Anthony J., Gunter, Jeffrey L. , Fields, Julie A. , Graff‐Radford, Jonathan, Ferman, Tanis J. , Murray, Melissa E. , Jack, Clifford R. , Petersen, Ronald C. , Boeve, Bradley F. , Tosakulwong, Nirubol , Graff‐Radford, Jonathan , Jones, David T. , Knopman, David S. , Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J

Mayo Clinic

Annals of Neurology | November 19, 2016 | Volume: 81 | Issue: 1 | Pages: 58-67

10.1002/ana.24825 | PMID 27863444 Get It

ObjectivePatients with probable dementia with Lewy bodies (DLB) often have Alzheimer's disease (AD)‐related pathology. Our objective was to determine the pattern of positron emission tomography (PET) tau tracer AV‐1451 uptake in patients with probable DLB, compared to AD, and its relationship to β‐amyloid deposition on PET.MethodsConsecutive patients with clinically probable DLB (n = 19) from the Mayo Clinic Alzheimer's Disease Research Center underwent magnetic resonance imaging, AV‐1451, and Pittsburgh compound‐B (PiB) PET examinations. Age‐ and sex‐matched groups of AD dementia (n = 19) patients and clinically normal controls (n = 95) from an epidemiological cohort served as a comparison groups. Atlas‐ and voxel‐based analyses were performed.ResultsThe AD dementia group had significantly higher AV‐1451 uptake than the probable DLB group, and medial temporal uptake completely distinguished AD dementia from probable DLB. Patients with probable DLB had greater AV‐1451 uptake in the posterior temporoparietal and occipital cortex compared to clinically normal controls, and in probable DLB, the uptake in these regions correlated with global cortical PiB uptake (Spearman rho = 0.63; p = 0.006).InterpretationMedial temporal lobe AV‐1451 uptake distinguishes AD dementia from probable DLB, which may be useful for differential diagnosis. Elevated posterior temporoparietal and occipital AV‐1451 uptake in probable DLB and its association with global cortical PiB uptake suggest an atypical pattern of tau deposition in DLB. ANN NEUROL 2017;81:58–67
[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, Jennifer L. , Lowe, Val J. , Tosakulwong, Nirubol , Weigand, Stephen D. , Senjem, Matthew L. , Schwarz, Christopher G. , Spychalla, Anthony J., Petersen, Ronald C. , Jack, Clifford R. , Josephs, Keith A. , Jack, Clifford R , Schwarz, Christopher G , Senjem, Matthew L

Mayo Clinic

Movement Disorders | October 27, 2016 | Volume: 32 | Issue: 1 | Pages: 124-133

10.1002/mds.26834 | PMID 27787958 Get It

ABSTRACTBackgroundThe [18F]AV‐1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy.ObjectivesThe objectives of this study were to determine whether [18F]AV‐1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia.Methods[18F]AV‐1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age‐ and gender‐matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV‐1451 imaging. Regional comparisons of [18F]AV‐1451 uptake were performed across the whole brain using region‐of‐interest and voxel‐level analyses, and correlations between regional [18F]AV‐1451 and the progressive supranuclear palsy rating scale were assessed.ResultsAn elevated [18F]AV‐1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV‐1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV‐1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale.ConclusionsProgressive supranuclear palsy is associated with an elevated [18F]AV‐1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia. © 2016 International Parkinson and Movement Disorder Society.
P3‐255: PET TAU Imaging with AV‐1451 in Microtubule‐Associated Protein TAU (MAPT) Mutation Carriers Relative to Alzheimer’S Disease Dementia and Controls
Lowe, Val J. , Wiste, Heather J. , Dheel, Christina, Wszolek, Zbigniew, Rademakers, Rosa , Petersen, Ronald C. , Boeve, Bradley F. , Jones, David T. , Senjem, Matthew L. , Kantarci, Kejal , Knopman, David S. , Wszołek, Zbigniew K. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2016.06.1918 Get It

P2‐178: Amyloid‐B, Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging
Pink, Anna , Roberts, Rosebud O., Vemuri, Prashanti, Christianson, Teresa J., Lowe, Val J. , Petersen, Ronald C. , Krell‐Roesch, Janina , Stokin, Gorazd B. , Mielke, Michelle M. , Jack, Clifford R. , Boeve, Bradley F. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2016.06.1345 Get It

O2‐05‐04: Resilience Factors for Amyloid Deposition and Neurodegeneration are Different
Lesnick, Timothy G. , Przybelski, Scott A. , Roberts, Rosebud O., Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Knopman, David S. , Machulda, Mary M. , Mielke, Michelle M. , Geda, Yonas E. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.420 Get It

IC‐P‐188: AV‐1451 TAU‐PET In Clinical Variants of Progressive Supranuclear Palsy
Josephs, Keith A. , Whitwell, Jennifer L. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2016.06.219 Get It

P1‐247: Network‐Based TAU Deposition Patterns are Related to Functional Network Failure Largely Via Beta‐Amyloid Across the Alzheimer’s Spectrum
Lowe, Val J. , Wiste, Heather J. , Radford, Jonathan Graff, Petersen, Ronald C. , Jones, David T. , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.996 Get It

O2‐08‐01: Av1451 Pet Imaging in the Spectrum of Alzheimer's Disease from Clinically Normal to Dementia
Wiste, Heather J. , Petersen, Ronald C. , Roberts, Rosebud O., Weigand, Stephen D. , Graff‐Radford, Jonathan , Lowe, Val J. , Knopman, David S. , Jack, Clifford R. , Boeve, Bradley F. , Kantarci, Kejal , Jones, David T. , Mielke, Michelle M. , Vemuri, Prashanthi , Machulda, Mary M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.436 Get It